Consistent with a role for hypertension in the progression of Alport syndrome, angiotensin‐converting enzyme (ACE) inhibitors have been used in a patient cohort and proven to be an effective therapeutic approach, especially when administered early in lifespan (Boeckhaus et al. 2022). This evidence concerns the gene ACE and hypertensive disorder.